DSC block and its application network structure. by Yingying Liu (360782)

“…The actual accuracy and mean latency time of the model were 92.43% and 260ms, respectively. …”

The structure of multi-scale residual block [30]. by Yingying Liu (360782)

“…The actual accuracy and mean latency time of the model were 92.43% and 260ms, respectively. …”

The structure of IRAU and Res2Net+ block [22]. by Yingying Liu (360782)

“…The actual accuracy and mean latency time of the model were 92.43% and 260ms, respectively. …”

Loss of C1-FDX results in a reduction of the CI and CV activity. by Baoyin Chen (2635399)

SPIRIT Schedule of Enrollment. by Asma Salari (21432948)

“…</p><p>Results</p><p>The EX group showed increased EMG activation for the tibialis anterior, gastrocnemius medialis, rectus femoris, and biceps femoris in both anterior-posterior (2.23 MVIC%, 95% CI: 1.13 to 3.34, p < 0.001) and posterior-anterior directions (2.35 MVIC%, 95% CI: 1.80 to 2.91, p < 0.001) compared to CO group. Onset time decreased significantly in the EX group relative to CO group (anterior-posterior: -108.07 ms, 95% CI: -117.23 to -98.89, p < 0.001; posterior-anterior: -98.72 ms, 95% CI: -106.54 to -90.90, p < 0.001). …”

Measuring muscle strength [49]. by Asma Salari (21432948)

“…</p><p>Results</p><p>The EX group showed increased EMG activation for the tibialis anterior, gastrocnemius medialis, rectus femoris, and biceps femoris in both anterior-posterior (2.23 MVIC%, 95% CI: 1.13 to 3.34, p < 0.001) and posterior-anterior directions (2.35 MVIC%, 95% CI: 1.80 to 2.91, p < 0.001) compared to CO group. Onset time decreased significantly in the EX group relative to CO group (anterior-posterior: -108.07 ms, 95% CI: -117.23 to -98.89, p < 0.001; posterior-anterior: -98.72 ms, 95% CI: -106.54 to -90.90, p < 0.001). …”

Details of aquatic exercise protocol. by Asma Salari (21432948)

“…</p><p>Results</p><p>The EX group showed increased EMG activation for the tibialis anterior, gastrocnemius medialis, rectus femoris, and biceps femoris in both anterior-posterior (2.23 MVIC%, 95% CI: 1.13 to 3.34, p < 0.001) and posterior-anterior directions (2.35 MVIC%, 95% CI: 1.80 to 2.91, p < 0.001) compared to CO group. Onset time decreased significantly in the EX group relative to CO group (anterior-posterior: -108.07 ms, 95% CI: -117.23 to -98.89, p < 0.001; posterior-anterior: -98.72 ms, 95% CI: -106.54 to -90.90, p < 0.001). …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Study on the expression of mRNA related to biofilm formation of <i>C. albicans</i> by CSR extract (100 μg/mL). by Xuxi Cheng (22453447)

Prediction of transition readiness. by Sharon Barak (4803966)

“…In most transition domains, help needed did not decrease with age and was not affected by function. …”

SEM images of cobalt-based catalysts supported on Al₂O₃ at different magnifications. by Ning Zuo (17295415)

Baseline analysis, nominal factors. by Hiroaki Yoshikawa (4615801)

“…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”

Minimal dataset for the study. by Hiroaki Yoshikawa (4615801)

“…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”

Baseline analysis, continuous factors. by Hiroaki Yoshikawa (4615801)

“…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”

Multivariable analysis between 2006 and 2018. by Hiroaki Yoshikawa (4615801)

“…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”

OVX educes bone density of femur. by Mingzhu Chen (6370013)

“…Compared to Sham rats, OVX tats had a significant decrease in bone mass and impaired bone micro structure: (L) BMD, (M) BV, (N) BV/TV, (O) Tb.N,(P) Tb.Sp, and (Q) Tb.Th. …”